CytomX Therapeutics, Inc.
COMBINED THERAPIES OF ACTIVATABLE IMMUNE CHECKPOINT INHIBITORS AND CONJUGATED ACTIVATABLE ANTIBODIES

Abstract:

Provided herein are compositions and methods relating to therapies that combine a conjugated activatable anti-CD 166 antibody that when activated specifically binds to CD 166 and an activatable immune checkpoint inhibitor. Also provided herein are compositions and methods relating to therapies that combine an activatable anti-immune checkpoint antibody that when activated specifically binds to the immune checkpoint and a conjugated activatable antibody, where the immune checkpoint is mammalian PD-1 or mammalian PD-L1.